Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic (original) (raw)
References
Bishop JM: The molecular genetics of cancer. Science 235:305–311, 1987 Google Scholar
Rhim JS: Viruses, oncogenes, and cancer. Cancer Detect Prev 11:139–149, 1988 Google Scholar
Nowell PC: Mechanisms of tumor progression. Cancer Res 46:2203–2207, 1986 Google Scholar
Nicolson GL: Tumor cell instability, diversification, and progression to the metastatic phenotype: From oncogene to oncofetal expression. Cancer Res 47:1473–1487, 1987 Google Scholar
Yarden Y, Ullrich AL: Growth factor receptor tyrosine kinases. Annu Rev Biochem 57:443–478, 1988 Google Scholar
Padhy L, Shih C, Cowing D, Finkelstein R, Weinberg RA: Identification of a phosphoprotein specifically induced by the transforming DNA of rat neuroblastomas. Cell 28:865–871, 1982 Google Scholar
Schechter AL, Stern DF, Vaidyanatha L, Decker SJ, Drebin JA, Greene MI, Weinberg RA: The neu oncogene: An erb-B related gene encoding a 185,000-Mr tumour antigen. Nature 312:513–516, 1984 Google Scholar
Bargmann CI, Hung MC, Weinberg RA: Multiple independent activations of the_neu_ oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649–657, 1986 Google Scholar
Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL: Human breast cancer: Correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 235:177–182, 1987 Google Scholar
Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press M: Studies of the HeR2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707–712, 1989 Google Scholar
Wright C, Angus B, Nicholson S, Sainsbury JRC, Cairns J, Gullick WJ, Kelley P, Harris AL, Horne CHW: Expression of cerbB-2 oncoprotein: A prognostic indicator in human breast cancer. Cancer Res 49:2087–2090, 1989 Google Scholar
Paik S, Hazan R, Fisher ER, Sass RE, Fisher B, Redmond C, Schlessinger J, Lippman ME, King CR: Pathologic findings from the national surgical adjuvant breast and bowel project: Prognostic significance of erbB-2 protein overexpression in primary breast cancer. J Clin Oncol 8:103–112, 1990 Google Scholar
Berchuck A, Kamel A, Whitaker R, Kerns B, Olt G, Kinney R, Soper JT, Dodge R, Clarke-Pearson DL, Marks P, McKenzie S, Yin S, Bast RC: Overexpression of HER2/neu is associated with poor survival in advanced epithelial ovarian cancer. Cancer Res 50:4087–4091, 1990 Google Scholar
Kern JA, Schwartz DA, Nordberg JE, Weiner DB, Greene MI, Torney L, Robinson RA: p185neu expression in human lung adenocarcinomas predicts shortened survival. Cancer Res 50:5184–5191, 1990 Google Scholar
Schlom J, Hand PH, Greiner JW, Colcher D, Shrivastav S, Carrasquillo JA, Reynolds JC, Larso SM, Raubitschek, A: Innovations that influence the pharmacology of monoclonal antibody guided tumor targeting. Cancer Res 50:820–827, 1990 Google Scholar
Szala S, Froehlich M, Scollon M, Kasai Y, Steplewski Z, Koprowski H, Linnenbach AJ: Molecular cloning of cDNA for the carcinoma-associated antigen GA733-2. Proc Natl Acad Sci 87:3542–3546
Di Fiore PP, Pierce JH, Kraus MH, Segatto O, King CR, Aaronson, SA: erbB-2 is a potent oncogene when overexpressed in NIH/3T3 cells. Science 237:178–182, 1987 Google Scholar
Hudziak RM, Schlessinger J, Ullrich A: Increased expression of the putative growth factor receptor p185HER2 causes transformation and tumorigenesis of NIH 3T3 cells. Proc Natl Acad Sci USA 84:7159–7163, 1987 Google Scholar
Hudziak RM, Lewis GD, Shalaby MR, Eessalu TE, Aggarwal BB, Ullrich A, Shepard HM: Amplified expression of the HER2/ErbB2 oncogene induces resistance to tumor necrosis factor-α in NIH3T3 cells. Proc Natl Acad Sci USA 85:5102–5106, 1988 Google Scholar
Urban JL, Shepard HM, Rothstein JL, Sugarman BJ, Schreiber H: Tumor necrosis factor: A potent effector molecule for tumor cell killing by activated macrophages. Proc Natl Acad Sci USA 83:5233–5237, 1986 Google Scholar
Shepard HM, Lewis GD: Resistance of tumor cells to tumor necrosis factor. J Clin Immunol 8:1–9, 1988 Google Scholar
Lichtenstein A, Berenson J, Gera JF, Waldburger K, Martiniz-Maza D, Berek JS: Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: Correlation with expression of HER2/neu oncogenes. Cancer Res 50:7364–7370, 1990 Google Scholar
Muller WJ, Sin E, Pattengale PK, Wallace R, Leder P: Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105–115, 1988 Google Scholar
Suda Y, Aizawa S, Furuta Y, Yagi T, Ikawa Y, Saitoh K, Yamada Y, Toyoshima K, Yamamoto T: Induction of a variety of tumors by c-erbB2 and clonal nature of lymphomas even with the mutated gene (Val659 Glu659). EMBO J 9:181–190, 1990 Google Scholar
Lupu R, Colomer R, Zugmaier G, Sarup J, Shepard M, Slamo D, Lippman ME: Direct intraction of a ligand for the erbB2 oncogene product with the EGF receptor and p185erbB2. Science 249:1552–1555, 1990 Google Scholar
Gill GN, Kawamoto T, Cochet C, Le A, Sato JD, Masui H, MacLeod C, Mendelsohn J: Monoclonal anti-epidermal growth factor receptor antibodies which are inhibitors of epidermal growth binding and antagonists of epidermal growth factor-stimulated tyrosine protein kinase activity. J Biol Chem 259:7755–7760, 1984 Google Scholar
Drebin JA, Link VC, Stern DF, Weinberg RA, Greene MI: Down-modulation of an oncogene protein product and reversion of the transformed phenotype by monoclonal antibodies. Cell 41:695–706, 1985 Google Scholar
Fendly BM, Winget M, Hudziak RM, Lipari MT, Napier MA, Ullrich A: Characterization of murine monoclonal antibodies reactive to either the human epidermal growth factor receptor or HER2/neu gene product. Cancer Res 50:1550–1558, 1990 Google Scholar
Mendelsohn J: Anti-EGF receptor monoclonal antibodies: Biological studies and potential clinical applications. Trans Am Clin Climatol Assoc 100:31–38, 1988 Google Scholar
Sarup JC, Johnson RM, King KL, Fendly BM, Lipari MT, Napier MA, Shepard HM: Growth regulation, 1991, in press
Hudziak RM, Lewis GD, Winget M, Fendly BM, Shepard HM, Ullrich A: p185HER2 monoclonal antibody has antiproliferative effects_in vitro_ and sensitizes human breast tumor cells to tumor necrosis factor. Mol Cell Biol 9:1165–1172, 1989 Google Scholar
Aboud-Pirak E, Hurwitz E, Pirak ME, Bellot F, Schlessinger J, Sela M: Efficacy of antibodies to epidermal growth factor receptor against KB carcinoma_in vitro_ and in nude mice. J Natl Cancer Inst 80:1605–1611, 1988 Google Scholar
Slamon D: Personal communication
Scott GK, Dodson JM, Johnson RM, Sarup JC, Fendly BM, Wong WL, Shepard HM, Benz CC: Manuscript in preparation
Ullrich A, Schlessinger J: Signal transduction by receptors with tyrosine kinase activity. Cell 61:203–212, 1990 Google Scholar